目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T68152 | Others | ||
Talmetacin 具有抗炎镇痛和抗肿瘤活性,可用于研究心血管疾病。 | |||
TN1582 | Antiviral | ||
Dihydromollugin 是在 Rubia cordifolia 中发现的萘甲酸酯,可能具有抗肿瘤、抑制病毒和其他活性。 | |||
T25969 | PLK | ||
Poloxin-2 是一种具有有效性和选择性的 Plk1 PBD 抑制剂,具有抗肿瘤活性,可降低HeLa细胞中Plk1的蛋白水平。 | |||
T83646 | Others | ||
(S)-OSMI 3 (Ent-OSMI-3) 具有抗炎抗肿瘤活性,可用以研究糖尿病和神经退行性疾病。 | |||
T7670 | COX | ||
Mavacoxib 是口服长效环氧合酶 2 选择性抑制剂,是长效的非甾体类抗炎药,用于犬退化性关节病相关的炎疼及痛症的研究。 | |||
T77728 | Microtubule Associated | ||
Tubulin polymerization-IN-55 是一种高效的 Tubulin Polymerization 抑制剂,具有潜在的抗血管生成和抗肿瘤活性,对 A549、K562、HepG2、MDA-MB-231 和 HFL-1 显示出抗增殖作用。 | |||
T61486 | DHFR | ||
DHFR-IN-4 是一种高效的二氢叶酸还原酶 (DHFR) 抑制剂,具有抗肿瘤活性,抑制 EGFR 和 HER2 ,可用于研究胰腺癌。 | |||
T2798 | Lipoxygenase Akt PI3K | ||
Esculetin (Cichorigenin) 是主要提取自水曲柳的树皮中的活性成分。它能够抑制PI3K/Akt 途径,阻碍血小板衍生生长因子诱导的气道平滑肌细胞表型转换。它具有抗氧化,抗炎和抗肿瘤的活性。 | |||
T7468 | Others | ||
(-)-α-Terpineol 是白葡萄酒中重要的香气化合物,是一种单萜化合物。 | |||
T64167 | FAK | ||
Ifebemtinib (BI-853520) 是一种具有口服活性和强效性的粘附斑激酶 (FAK) 抑制剂 (IC50=1 nM),具有抗肿瘤活性,可抑制恶性胸膜间皮瘤中的球状体形成和原位肿瘤生长,可用于研究乳腺癌和卵巢癌。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02848 | Adiponectin Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPY-05556 | Adiponectin Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00455 | IGF1R/CD221 Protein, Human, Recombinant (His & Avi) | Human | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPK-00658 | IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPK-00456 | IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated | Human | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPY-01681 | Adiponectin Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPY-02922 | XIAP Protein, Human, Recombinant (His) | Human | E. coli | ||
E3 ubiquitin-protein ligase XIAP / BIRC4, also known as an inhibitor of apoptosis protein 3, X-linked inhibitor of apoptosis protein, and IAP-like protein, is a protein that belongs to a family of apoptotic suppressor proteins. Members of this family share a conserved motif termed, baculovirus IAP repeat, which is necessary for their anti-apoptotic function. XIAP / BIRC4 functions through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and interleukin 1-beta converting enzyme. XIAP / BIRC4 also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. Mutations in this encoding gene are the cause of X-linked lymphoproliferative syndrome. Alternate splicing results in multiple transcript variants. Thought to be the most potent apoptosis suppressor, XIAP / BIRC4, directly binds and inhibits caspases -3, -7 and -9. Survivin, which also binds to several caspases, is up-regulated in a many tumour cell types. Defects in XIAP / BIRC4 are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2). XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
|
|||||
TMPY-01216 | XIAP Protein, Human, Recombinant (Avi) | Human | E. coli | ||
E3 ubiquitin-protein ligase XIAP / BIRC4, also known as an inhibitor of apoptosis protein 3, X-linked inhibitor of apoptosis protein, and IAP-like protein, is a protein that belongs to a family of apoptotic suppressor proteins. Members of this family share a conserved motif termed, baculovirus IAP repeat, which is necessary for their anti-apoptotic function. XIAP / BIRC4 functions through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and interleukin 1-beta converting enzyme. XIAP / BIRC4 also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. Mutations in this encoding gene are the cause of X-linked lymphoproliferative syndrome. Alternate splicing results in multiple transcript variants. Thought to be the most potent apoptosis suppressor, XIAP / BIRC4, directly binds and inhibits caspases -3, -7 and -9. Survivin, which also binds to several caspases, is up-regulated in a many tumour cell types. Defects in XIAP / BIRC4 are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2). XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
|